Skip to main content

Table 5 Correlation between PIK3CA mutation status and response to neoadjuvant FAC/FEC or TFAC/TFEC chemotherapies

From: PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

   FAC/FECa chemotherapy TFAC/TFECa chemotherapy
   PIK3CA wild-type (n = 51) PIK3CA mutation (n = 12) P valueb PIK3CA wild-type (n = 66) PIK3CA mutation (n = 11) P valueb
Pathological complete response (pCR) versus residual disease (RD) RD 48 (94%) 11 (92%) 1.000 47 (73%) 7 (70%) 1.000
  pCR 3 (6%) 1 (8%)   17 (27%) 3 (30%)  
  Unknown - - - 2 1 -
Residual cancer burden 0 6 (17.6%) 1 (16.7%) 0.334 (0.474c) 14 (24.6%) 3 (33.3%) 0.438 (0.613c)
  I 2 (5.9%) 0 (0%)   5 (8.8%) 0 (0%)  
  II 16 (47.1%) 5 (83.3%)   21 (36.8%) 5 (55.6%)  
  III 10 (29.4%) 0 (0%)   17 (29.8%) 1 (11.1%)  
  Unknown 17 6 - 9 2 -
  1. aFor description, please refer to text. bChi-square test. c P value for comparison of residual cancer burden (RCB)-0 and RCB-I versus RCB-III. FAC, 5-fluoruracil, doxorubicin, and cyclophosphamide; FEC, 5-fluoruracil, epirubicin, and cyclophosphamide; PIK3CA, phosphatidylinositol 3-kinase, catalytic, alpha polypeptide; TFAC, paclitaxel followed by 5-fluoruracil, doxorubicin, and cyclophosphamide; TFEC, paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide.